PH West Utah Pulmonary Hypertension Symposium

This live accredited activity is the only Mountain West symposium that focuses on the changing epidemiology of pulmonary vascular disease, discusses the role of genetics and epigenetics of various forms of Pulmonary Hypertension, and provides context and guidance for how to incorporate evolving treatment pathways.

This education is provided by leading physicians, researchers, and guideline authors in the field of pulmonary hypertension through a combination of didactic lectures, debates, and lively panel discussions.

Utah is well suited to host this conference with a long established history of pioneering genetic studies and outcomes research, and is at the forefront for the management of the methamphetamine epidemic.

Objectives

After completing this activity, the participant should be better able to:

• Describe the unique challenges presented by methamphetamine-associated PAH, including treatment of substance use disorders and collaborative care models
• Examine care delivery models in differing PAH populations, and the impact of regional variability on patient outcomes
• Discuss the use of combination therapies, transition treatment strategies, and add-on treatments in the management of PAH
• Increase awareness of treatment approaches and the importance of timely diagnosis of PH in ILD patients
• Appreciate the importance of risk stratification and goal-directed therapies in the management of PAH
• Consider the relevance and impact of the 7th World Symposium on Pulmonary Hypertension on diagnosis and treatment of PAH
• Provide guidance on the relevance of anti-proliferative agents and vasodilators in modern clinical practice